Phaseline

Companies › Portal Therapeutics

Portal Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PORT-77
PPIX (protoporphyrin IX) level reduction
–Phase 2Erythropoietic Protoporphyria (EPP)Mar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07820085PORT-77Phase 2Erythropoietic Protoporphyria (EPP)Metabolic and endocrineMar 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Op-T Housey Healthcare ULC Mankind Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.